Meticulous initial clinical and pathological staging with standardized long-term follow-up after radical cystectomy is required to validate and improve overall prognostic performance in patients undergoing neoadjuvant chemotherapy for bladder cancer
Minerva Urol Nephrol
.
2024 Feb;76(1):124-126.
doi: 10.23736/S2724-6051.23.05563-5.
Epub 2024 Jan 9.
Authors
Marc A Furrer
1
2
3
4
5
6
,
Christopher Soliman
7
,
Patrick Y Wuethrich
8
Affiliations
1
Department of Urology, Bern University Hospital, University of Bern, Bern, Switzerland -
[email protected]
.
2
Department of Urology, Solothurner Spitäler AG, Olten, Switzerland -
[email protected]
.
3
Kantonsspital Olten, Olten, Switzerland -
[email protected]
.
4
Bürgerspital Solothurn, Olten, Switzerland -
[email protected]
.
5
Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland -
[email protected]
.
6
Department of Urology, Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia -
[email protected]
.
7
Department of Urology, Royal Melbourne Hospital, The University of Melbourne, Victoria, Australia.
8
Department of Anesthesiology and Pain Medicine, Bern University Hospital, University of Bern, Bern, Switzerland.
PMID:
38193744
DOI:
10.23736/S2724-6051.23.05563-5
No abstract available
MeSH terms
Cystectomy*
Follow-Up Studies
Humans
Neoadjuvant Therapy
Prognosis
Urinary Bladder Neoplasms* / drug therapy
Urinary Bladder Neoplasms* / pathology
Urinary Bladder Neoplasms* / surgery